Clinical Trials

Ketamine-Augmented Psychotherapy and Neurocognition in Unipolar Depression: 2026 Scoping Review

A systematic mapping of studies on neurocognitive outcomes in adults with unipolar depression treated with ketamine-augmented psychotherapy, highlighting research gaps and future trial design needs.

Published November 17, 2026 Read 3 min 745 words By The Psychedelic Journal Reviewed by Dr. Michael Teplitsky

Scoping Review Maps Neurocognitive Outcomes of Ketamine-Augmented Psychotherapy in Depression

A November 2026 scoping review, published via OpenAlex (W7237125247), systematically maps the existing evidence on neurocognitive outcomes in adults with unipolar depressive disorders treated with ketamine-augmented psychotherapy (KAP). This review does not provide pooled efficacy estimates, but instead catalogs the breadth, methods, and gaps in the literature, focusing on both objective and subjective cognitive changes associated with KAP protocols. The review covers studies published since 2000, marking the year of the first placebo-controlled trial of ketamine in depression, and applies the PRISMA-ScR and JBI scoping review frameworks.

Mechanisms, Study Designs, and Clinical Context

Ketamine-augmented psychotherapy involves protocol-defined administration of ketamine or esketamine in combination with structured psychotherapeutic interventions, distinguishing it from studies using ketamine alone or with only supportive contact. The review highlights that unipolar depression is not only characterized by affective symptoms, but also by neurocognitive deficits in domains such as attention, memory, processing speed, and executive function. These cognitive difficulties can persist even after mood symptoms improve with conventional antidepressants, underscoring the clinical importance of targeting cognition as a treatment goal.

By mapping studies that used both objective neurocognitive measures (e.g., standardized cognitive tests) and subjective assessments (e.g., patient-reported outcomes), the review provides a nuanced picture of how KAP may influence cognitive function in this population. The included studies vary widely in their ketamine protocols, psychotherapy modalities, assessment timepoints, and populations—especially with respect to treatment-resistant depression (TRD) versus broader unipolar depression samples.

Policy and Research Implications

The main policy and research implication of this scoping review is its identification of substantial methodological heterogeneity and evidence gaps in the KAP literature. For researchers, the review offers a roadmap for future clinical trial design by cataloging which cognitive domains and outcome measures have been studied, and where evidence is sparse or absent. For example, the review notes that many studies fail to distinguish between TRD and non-TRD populations, or do not report long-term cognitive outcomes, limiting the generalizability of findings to real-world clinical practice.

For clinicians and trial sponsors, the review's systematic approach provides a reference point for protocol development and outcome selection, especially as regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly emphasize cognitive and functional endpoints in psychiatric drug development. However, the review itself does not change the legal status of ketamine or KAP, nor does it provide treatment recommendations or efficacy claims.

Risks, Limitations, and Unknowns

The scoping review makes clear that the evidence base for neurocognitive effects of KAP in unipolar depression remains fragmented and methodologically inconsistent. Risks associated with ketamine administration—including dissociation, blood pressure increases, and potential for misuse—are not systematically addressed in the mapped studies, reflecting a broader limitation in the literature. Furthermore, the review highlights that many studies are short-term, lack active comparators, or use small sample sizes, raising concerns about the robustness and external validity of reported cognitive outcomes.

Another key limitation is the lack of standardized cognitive assessment tools and harmonized outcome reporting, which impedes cross-study comparisons and synthesis. The review also notes that the majority of studies focus on immediate or short-term cognitive changes, with little data on sustained or delayed effects, and few studies examine the interaction between cognitive and psychosocial functioning over time.

Looking Ahead: Priorities for Clinical Trials and Practice

The scoping review underscores the urgent need for rigorously designed, adequately powered randomized controlled trials (RCTs) of KAP in unipolar depression, with harmonized cognitive endpoints and longer follow-up periods. Researchers are encouraged to clearly define patient populations (e.g., TRD vs. non-TRD), specify psychotherapeutic modalities, and adopt standardized cognitive batteries to facilitate meta-analysis and regulatory review. For policymakers and funders, the review provides a foundation for prioritizing research investments that address the most critical gaps in the evidence base, such as long-term cognitive safety and functional outcomes.

Finally, the review's methodological transparency—particularly its use of the Population–Concept–Context (PCC) framework and explicit eligibility criteria—serves as a model for future evidence syntheses in the rapidly evolving field of psychedelic-assisted therapies. As the field matures, systematic mapping of evidence will be essential to guide both clinical innovation and regulatory oversight.

Reviewed by Dr. Alex Meyer, PhD (Neuroscience), on 2026-11-18. Sources: OpenAlex scoping review (W7237125247), FDA guidance on psychiatric drug development, PRISMA-ScR reporting standards.

Primary source: https://openalex.org/W7237125247 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.